Parker Institute Strengthens Leadership with Bolyn Hubby's Appointment as Chief of Staff

Parker Institute for Cancer Immunotherapy: A New Era with Bolyn Hubby

The Parker Institute for Cancer Immunotherapy (PICI) recently announced a significant addition to its leadership team: Dr. Bolyn Hubby has been appointed as the new Chief of Staff. This move comes at a pivotal moment for PICI as it embarks on its 10th year dedicated to redefining cancer treatments through innovative immunotherapy.

Strengthening Mission and Strategy

Dr. Hubby's appointment is strategic, aimed at enhancing PICI's organizational excellence during a period marked by growth and change. She will collaborate closely with CEO Karen E Knudsen, Ph.D., to steer PICI's priorities and juice up operational alignment across various functions. The goal is clear: to propel the organization’s mission to develop and advance groundbreaking therapies for cancer patients.

In her new role, Dr. Hubby aims to engage deeply with all divisions within PICI, ensuring that high-impact initiatives are seamlessly integrated and executed. She expressed her enthusiasm about joining the team, stating, “I am honored to join the PICI team at such a pivotal moment in cancer immunotherapy.” Her vision aligns with the organization's commitment to transforming all cancers into curable diseases, leveraging the community of scientists and industry partners to achieve this ambitious goal.

An Experienced Leader

Bringing over 20 years of experience in biotechnology, Dr. Hubby has an impressive track record in sectors that include infectious diseases, immunology, and cancer immunotherapy. Prior to her position at PICI, she served as the Executive Vice President and Chief Corporate Affairs Officer at Vir Biotechnology. There, she specialized in government affairs and corporate communications, as well as fostering significant public-private partnerships that are often critical in the healthcare sector.

Her past roles have also included being the Chief Scientific Officer at Agenovir Corporation and various leadership positions at Synthetic Genomics, Liquidia Technologies, and AlphaVax. These experiences have given her a robust understanding of transitioning research from theory to clinical applications, a key aspect for PICI as it works to bring innovative cancer therapies into practical use.